Charlene Bruno

Charlene Bruno is a seasoned professional in regulatory affairs with extensive experience in the biopharmaceutical industry. Currently serving as Senior Director of Regulatory CMC Biologics at Prothena Corporation plc since January 2023, Charlene leads CMC regulatory strategies and content development for a portfolio of large molecules in clinical development. Prior roles include Director of Regulatory CMC Biologics at Jazz Pharmaceuticals, where Charlene managed regulatory strategies for a biological portfolio, and Associate Director positions at Merck and Peregrine Pharmaceuticals, focusing on regulatory approvals and strategies for biological products. Charlene's education includes a Master of Science in Pharmaceutical Sciences from Temple University and a Bachelor of Science in Biology from Ursinus College.